Wall Street Analysts Believe Day One Biopharmaceuticals (DAWN) Could Rally 161.36%: Here's is How to Trade

Day One Biopharmaceuticals, Inc. (DAWN) closed the last trading session at $8.8, gaining 22.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $23 indicates a 161.4% upside potential.The average comprises eight short-term price targets ranging from a low of $16.00 to a high of $29.00, with a standard deviation of $4.93. While the lowest estimate indicates an increase of 81.8% from ...